SENORES

Senores Pharmaceuticals Limited

Source: NSE · Updated 4 Nov, 06:28 pm IST

Filed 29 Oct, 06:50 pm IST Q2 FY27 (Sep ’26)Consolidated₹ crores

Revenue

192.33

▲ 18.9% vs Q2 FY26

Operating profit (EBITDA, derived from filing)

57.66

▲ 16.5% vs Q2 FY26

Net profit

36.6

▲ 21.5% vs Q2 FY26

EPS (₹)

8.85

▲ 35.3% vs Q2 FY26

Operating margin

30.0%

−60 bps vs Q2 FY26

Net margin

19.0%

+40 bps vs Q2 FY26

Revenue up, profit up vs Q2 FY26

Revenue+19% vs Q2 FY26 · +7% vs Q1 FY27

Profit+22% vs Q2 FY26 · +20% vs Q1 FY27

View official filing ↗

Numbers from the company's structured XBRL filing on NSE, cross-checked with P&L totals.

Previous-quarter and year-ago figures: as originally reported in those quarters' NSE filings; filing PDF not available to confirm restatements.

Quarter comparison

Item	Q2 FY27 (Sep ’26)	Q1 FY27 (Jun ’26)	vs Q1 FY27	Q2 FY26 (Sep ’25)	vs Q2 FY26
Revenue from operations	192.33	180.21	▲ 6.7%	161.76	▲ 18.9%
Other income	8.94	2.81	▲ 218.1%	5.41	▲ 65.2%
Total income	201.27	183.02	▲ 10.0%	167.17	▲ 20.4%
Total expenses	153.69	143.56	▲ 7.1%	126.53	▲ 21.5%
Operating profit (EBITDA)*	57.66	53.76	▲ 7.3%	49.51	▲ 16.5%
Profit before tax	47.58	39.46	▲ 20.6%	40.64	▲ 17.1%
Tax expense	10.98	9.01	▲ 21.9%	10.52	▲ 4.4%
Net profit	36.6	30.45	▲ 20.2%	30.12	▲ 21.5%
EPS (₹)	8.85	6.61	▲ 33.9%	6.54	▲ 35.3%
Operating margin	30.0%	29.8%	+20 bps	30.6%	−60 bps
Net margin	19.0%	16.9%	+210 bps	18.6%	+40 bps

Showing Q2 FY27 (Sep ’26) and change vs Q2 FY26. Turn your phone sideways for Q1 FY27 (Jun ’26).

Figures in ₹ crores except EPS. Consolidated figures from the company's XBRL filing on NSE. Each row is shown only if it reconciles with the others (e.g. PBT − tax = net profit); rows we couldn't verify are left out. Net margin = net profit ÷ revenue. *Operating profit (EBITDA), derived from the filing: profit before exceptional items and tax + finance costs + depreciation − other income. Operating margin = EBITDA ÷ revenue.

All Senores Pharmaceuticals results, dividends & filings ›

Other results filed 29 Oct

ACI Archean Chemical Industries Limited›KALPATARU Kalpataru Limited›SUDARSHAN Sudarshan Pharma Industries Limited›STLNETWORK STL Networks Limited›LAURUSLABS Laurus Labs Limited›SURYODAY Suryoday Small Finance Bank Limited›ARCIL Asset Reconstruction Company (India) Limited›RBA Restaurant Brands Asia Limited›ASIANPAINT Asian Paints Limited›MONARCH Monarch Networth Capital Limited›CARERATING CARE Ratings Limited›AYMSYNTEX AYM Syntex Limited›

Today's results ›

SENORES PHARMACEUTICALS Q2 FY27 ; NET PROFIT UP 22% AT ₹37 CR (YOY), UP 20% (QOQ)

REVENUE UP 19% AT ₹192 CR (YOY), UP 7% (QOQ)

EBITDA UP 16% AT ₹58 CR (YOY), UP 7% (QOQ)

MARGINS AT 30.0% VS 30.6% (YOY), 29.8% (QOQ)

https://resultkal.com/r/senores-2026-10-29
Source: NSE filing · not investment advice

FAQ

When did Senores Pharmaceuticals announce Q2 FY27 results?

Senores Pharmaceuticals filed its results on NSE on 29 Oct, 06:50 pm IST.

What does QoQ and YoY mean?

QoQ compares with the previous quarter; YoY compares with the same quarter last year. Growth is calculated from the figures in the filing.

Are these Senores Pharmaceuticals figures official?

They are auto-read from the company's NSE filing and may contain errors. Always confirm with the official PDF linked on this page.

Explore

Today's results Results this week Q2 FY27 results dates Dividend stocks this week Bonus issue 2026 Stock split 2026

Figures are auto-read from the company's NSE filing and may contain errors. Check the official filing before deciding. Not investment advice.

← SENORES overview